Abstract
A bispecific antibody directed to T and B cells (CD3 x CD19 bsAb) was daily infused intravenously in escalating doses from 10 micrograms up to 5 mg in three patients with chemotherapy-resistant non-Hodgkin lymphoma; in this way we aimed to activate T cells to kill the malignant B cells. Only limited toxicity was observed, consisting of moderate fever preceded by chills or shivers and mild thrombocytopenia. No human anti-(mouse Ig) antibodies were found. Pharmacokinetics showed a t1/2 of 10.5 h with peak levels of 200-300 ng/ml after infusion of 2.5 mg bsAb. bsAb in serum was functionally active in vitro. After bsAb infusion a rise in serum tumour necrosis factor alpha was observed, accompanied by an increase in soluble CD8 and to some extent in soluble interleukin-2 receptor (IL-2R), but not in interferon gamma. IL-4 or soluble CD4. No evidence was found for monocyte activation (no increases in IL-6, IL-8 or IL-1 beta in serum). No gross changes in histology or number of IL-2R+, CD4+ or CD8+ cells were found in the lymph nodes after therapy, but one patient showed activated CD8+ T cells within the tumour nodules. In conclusion, after intravenously administered CD3 x CD19 bsAb only moderate toxicity was found, probably due to CD...Continue Reading
References
Dec 1, 1992·Clinical and Experimental Immunology·I A HaagenB de Gast
Aug 1, 1992·Immunobiology·D M SegalJ R Wunderlich
Feb 1, 1992·The American Journal of Medicine·S SawadaT Obara
Jan 1, 1991·Cancer Immunology, Immunotherapy : CII·A HekmanC J Melief
Dec 1, 1991·Journal of Clinical Pathology·T M VroomJ Borst
Jul 1, 1991·Clinical Immunology and Immunopathology·J A SymonsG W Duff
Nov 1, 1991·The Journal of Clinical Investigation·I KuraneF A Ennis
Feb 17, 1990·Lancet·T NittaS Ishii
Jun 1, 1990·Immunology Today·C H JuneC B Thompson
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·F M Uckun, J A Ledbetter
Feb 1, 1989·European Journal of Immunology·M ClarkH Waldmann
Jan 1, 1989·Annual Review of Immunology·D L MuellerR H Schwartz
Jun 16, 1988·Nature·T W HuizingaP A Tetteroo
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T YoshimuraE J Leonard
Dec 1, 1994·Cancer Immunology, Immunotherapy : CII·I A HaagenB C de Gast
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Oct 1, 1994·British Journal of Cancer·B J KroesenN H Mulder
Aug 16, 1994·Proceedings of the National Academy of Sciences of the United States of America·F NakajimaM Suthanthiran
Jan 1, 1994·Immunology Today·G D BeunG J Fleuren
Jun 16, 1993·Journal of the National Cancer Institute·J G TibbenL F Massuger
Citations
Feb 13, 1999·International Journal of Cancer. Journal International Du Cancer·S MiottiS Canevari
Feb 21, 2007·Cancer Immunology, Immunotherapy : CII·Christian BrandlRobert Hofmeister
May 10, 2007·Cancer Immunology, Immunotherapy : CII·Freddy Tita-NwaMartin Kornacker
Apr 18, 2000·Hybridoma·J KriangkumM R Suresh
Oct 1, 1995·Journal of Hematotherapy·G C De GastB J Bast
Feb 17, 2009·Journal of Experimental & Clinical Cancer Research : CR·Michael A StröhleinMarkus M Heiss
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Jan 26, 2000·British Journal of Cancer·G MolemaL F de Leij
Jul 3, 1998·International Journal of Cancer. Journal International Du Cancer·B K LinkG J Weiner
Oct 20, 2005·Blood·Shoshana MoreckiShimon Slavin
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Feb 5, 2019·Current Oncology Reports·Roberta Demichelis-GómezChristianne Bourlon
Apr 22, 2020·Cellular & Molecular Immunology·Heliang LiErwei Song
Nov 27, 2018·Southern African Journal of HIV Medicine·Brian T FlepisiBernd Rosenkranz
Dec 30, 1998·Leukemia & Lymphoma·F HartmannM Pfreundschuh
Nov 2, 2002·Blood·Shigeto YoshidaAkira Ishii
Jul 9, 2013·Oncology Letters·Lin ZhangKunpeng Zhang
Jun 6, 2000·Journal of Immunotherapy·P LefterovaI G Schmidt-Wolf
Apr 5, 2016·Biochemical and Biophysical Research Communications·Chia-Yen LuChuan-Lung Hsu